Evommune, Inc. files regulatory documents covering its clinical-stage biotechnology business, public-company governance and capital structure. Its 8-K filings furnish operating and financial results, Regulation FD corporate presentations, material-event disclosures and clinical updates for pipeline programs including EVO756 and EVO301.
Evommune’s SEC record also includes registration materials tied to common stock offerings and proxy materials for annual meeting matters. These filings document director elections, auditor ratification, shareholder voting procedures, capital-structure disclosures, material agreements, clinical and regulatory disclosures, and risk factors associated with developing therapies for chronic inflammatory diseases.
Evommune, Inc. President & CEO Luis C. Pena acquired 1,115 common shares on September 30, 2026, through the non-qualified component of the company’s 2025 Employee Stock Purchase Plan. The shares were purchased at $7.02 per share, equal to 85% of the issuer’s closing price that day. Pena directly held 631,573 shares following the transaction. He reported that the transaction was reported late due to an administrative oversight.
Evommune, Inc. reported Phase 2a proof-of-concept results for EVO301 in adults with moderate-to-severe atopic dermatitis. The 70-patient trial used intravenous doses of 5 mg/kg at baseline and Week 4, with 48 patients receiving EVO301 and 22 receiving placebo. At Week 12, eight weeks after the last dose, the least-squares mean EASI reduction from baseline was 55% with EVO301 versus 22% with placebo (p<0.01); reported reductions at Weeks 4 and 8 were 41% versus 18% and 50% versus 16%.
At Week 12, EASI-50 responses were 63% versus 23%, and EASI-75 responses were 29% versus 9%. Treatment-related adverse events occurred in 10.4% of EVO301-treated patients and 13.6% of placebo patients. Evommune reported no treatment-related serious or severe adverse events, no discontinuations due to adverse events, no clinically significant laboratory abnormalities, and no conjunctivitis. The company plans to initiate a subcutaneous, dose-ranging Phase 2b trial in mid-2027.
Evommune, Inc. announced that data from its Phase 2a trial of EVO301 in moderate-to-severe atopic dermatitis will be presented in a late-breaking oral session at the 2026 European Academy of Dermatology & Venereology Congress in Vienna. The congress runs September 30 to October 3, 2026, with the presentation scheduled for October 1, 2026.
EVO301 is a long-acting injectable SAFA-IL-18BP fusion protein designed to neutralize aberrantly upregulated IL-18 activity. Evommune said its Phase 2b dose-ranging study in moderate-to-severe atopic dermatitis is anticipated to begin in mid-2027.
Evommune, Inc. (EVMN) furnished an updated corporate presentation outlining its strategy to treat chronic inflammatory and immunological diseases through three main programs: EVO301 (an IL‑18 binding protein biologic for atopic dermatitis and other IL‑18–driven diseases), EVO756 (an oral MRGPRX2 antagonist for migraine prevention) and EVO646 (an oral TLR7/8 antagonist for autoimmune diseases).
The presentation reports Phase 2a proof‑of‑concept data for EVO301 in moderate‑to‑severe atopic dermatitis in 70 adults, showing a 34% placebo‑adjusted EASI improvement at week 8 (33% at week 12), with 23% of patients achieving IGA 0/1 at week 12 versus 0% on placebo and no treatment‑related serious or severe adverse events; a Phase 2b subcutaneous dose‑ranging trial is planned to start in mid‑2027. For EVO756, Evommune describes completed Phase 1 and proof‑of‑concept work and an ongoing Phase 2b migraine prevention trial in approximately 330 patients, with top‑line data expected in 2027, while EVO646 is being advanced toward a Phase 1 start in the first half of 2027.
Evommune highlights an estimated $287 million in cash and investments with an expected runway into 2029, large target markets in atopic dermatitis, migraine and autoimmune diseases, and a leadership team that has held key roles in nearly 30 prior NDA and BLA approvals.
Evommune, Inc. (EVMN) filed a prospectus supplement incorporating a Current Report that discloses top-line results from a Phase 2b trial of oral MRGPRX2 antagonist EVO756 in adults with moderate-to-severe atopic dermatitis. The randomized, double-blind, placebo-controlled, dose-ranging study enrolled 121 adults over a 12-week treatment period with follow-up through Week 14 and did not meet its primary or secondary endpoints at any dose tested.
Based on these results, Evommune plans to cease development of EVO756 for atopic dermatitis but will continue to evaluate the drug in migraine prophylaxis. The company states that, given its revised clinical development plans, current cash, cash equivalents, and investments are expected to fund operations into 2029. The supplement also notes that Evommune’s common stock trades on the NYSE under the symbol EVMN, with a last reported sale price of $13.08 per share on September 8, 2026.
Evommune, Inc. (EVMN) reported top-line data from a randomized, double-blind, placebo-controlled, dose-ranging Phase 2b trial of oral MRGPRX2 antagonist EVO756 in adults with moderate-to-severe atopic dermatitis. The 12‑week study in 121 patients did not meet its primary or secondary endpoints at any dose, and Evommune plans to cease development of EVO756 for atopic dermatitis while continuing to evaluate it in migraine prophylaxis.
The company highlighted EVO301, an IL‑18BP fusion protein, as its lead atopic dermatitis program after positive Phase 2a proof‑of‑concept data and plans a Phase 2b trial starting in mid‑2027. Based on revised clinical plans, Evommune expects its current cash, cash equivalents and investments to fund operations into 2029.
Evommune, Inc. received an amended Schedule 13G disclosure from BioDiscovery 6 FPCI, Andera Partners, Stephane Bergez and Francois Xavier Mauron regarding their holdings of Evommune common stock. BioDiscovery 6 is the record holder of 1,391,990 shares of common stock, which the reporting persons may be deemed to beneficially own through Andera as management company and its managing partners, Bergez and Mauron.
This position represents 3.9% of Evommune’s common stock, based on 36,018,372 shares outstanding as of May 5, 2026. The reporting persons report shared voting and dispositive power over 1,391,990 shares and no sole voting or dispositive power. They state that they own 5% or less of the class and expressly disclaim status as a group.
T. Rowe Price Associates, Inc. reports beneficial ownership of common stock of Evommune Inc. The firm holds 1,940,939 shares, representing 5.4% of the company’s common stock outstanding. All reported shares are subject to T. Rowe Price’s sole voting and sole dispositive power, with no shared voting or dispositive authority.
T. Rowe Price states that this report should not be construed as an admission that it is the beneficial owner of these securities, and such beneficial ownership is expressly denied.
Evommune, Inc. reports substantially higher operating spend and losses as it advances multiple inflammatory-disease programs. For the quarter ended June 30, 2026, it generated no revenue and recorded a net loss of $32.2 million, or $0.89 per share, driven by research and development expenses of $26.4 million and general and administrative expenses of $8.5 million.
For the first half of 2026, the net loss was $53.9 million. In June 2026, a Phase 2b trial of EVO756 in chronic spontaneous urticaria failed to meet its primary endpoint, and Evommune will cease that indication, while continuing Phase 2b studies in atopic dermatitis and migraine. A February 2026 private placement raised $117.2 million, contributing to $288.0 million in cash, cash equivalents and investments at June 30, 2026, which management expects will fund operations under the current plan through 2028.
Evommune, Inc. is a clinical-stage biotech developing therapies for chronic inflammatory diseases, with lead programs EVO756 and EVO301 in Phase 2 development. In June 2026, a Phase 2b trial of EVO756 in chronic spontaneous urticaria failed its primary endpoint, and development for that indication is being discontinued. EVO756 development continues in atopic dermatitis and migraine, with a Phase 2b AD readout expected in September 2026 and a new global Phase 2b migraine prophylaxis trial underway.
For the quarter ended June 30, 2026, Evommune reported no revenue, research and development expenses of $26,412 thousand and general and administrative expenses of $8,483 thousand, leading to a net loss of $32,246 thousand, compared with $13,565 thousand a year earlier. For the first half of 2026, the net loss was $53,920 thousand versus $28,122 thousand in 2025, reflecting higher clinical and public-company costs and the absence of prior-year license revenue.
Liquidity has strengthened following a February 2026 private placement of 4,494,279 shares at $27.88 per share, providing net proceeds of approximately $117.2 million. As of June 30, 2026, cash, cash equivalents and investments totaled $288.0 million, which management expects will fund operations and capital needs into 2028. The company also highlights evolving legal and compliance risks around its and partners’ use of AI technologies.